Medical Treatments in Patients With Ambulatory Heart Failure: First Data From the BRING-UP-3 Heart Failure Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Oliva Fabrizio, Orso Francesco, Colivicchi Furio, Cipriani Manlio Gianni, DI Lenarda Andrea, Gabrielli Domenico, Gori Mauro, Gorini Marco, Iacoviello Massimo, Lucci Donata, Marini Marco, Amico Francesco, Bertoli Daniele, Carigi Samuela, D'Elia Emilia, DI Fusco Stefania Angela, Fucili Alessandro, Lanati Gianluca, Menegato Alessandra, Moretti Michele, Navazio Alessandro, Passantino Andrea, Pulignano Giovanni, Ruzzolini Matteo, Scardovi Angela Beatrice, Somaschini Alberto, Maggioni Aldo Pietro, on the behalf of BRING-UP-3 Heart Failure Investigators
Аннотация
OBJECTIVES: The BRING-UP-3 Heart Failure (HF) study was designed to guide the Guideline-implementation recommendations for patients with HF enrolled in a large sample of Italian cardiology sites.
METHODS: The BRING-UP-3 HF study is an observational, prospective, nationwide investigation encompassing 179 sites and enrolling ambulatory and hospitalized patients with HF. The study includes an educational intervention followed by 2 3-month enrolment periods and by a 6-month follow-up period with end-point evaluation. For patients with HFrEF, the objective is to describe the proportion of patients who receive the 4 pillars. Here we present the baseline data of the ambulatory cohort.
RESULTS: A total of 3830 ambulatory patients were included in the study. The mean age was 70 ± 12 years (34.5% older than 75 years), females were 21.9%. The most prevalent group was HFrEF (58.4%), followed by HFimpEF (17.4%), HFmrEF (14.4%), and HFpEF (9.8%). Hypertension, atrial fibrillation, diabetes mellitus, and chronic kidney disease were reported in 68.2%, 40.4%, 31.0%, and 33.1%, respectively. In patients with HFrEF, a high prescription rate (65%) for the 4 therapeutic pillars was observed; beta-blockers and RASis (mostly ARNIs) were prescribed in over 90%, while SGLT2is and MRAs were prescribed in over 80% of cases. In HFmrEF and HFpEF, SGLT2i prescription rates reached 72.1% and 50.1%, respectively.
CONCLUSIONS: A comprehensive analysis of a large sample of Italian cardiology sites revealed a high prevalence of prescription of guideline-recommended treatments.
CLINICALTRIAL: GOV: NCT06279988.